Table 2. Patient features by data source.
| Features | METABRIC | TCGA |
|---|---|---|
| (N = 772) | (N = 650) | |
| Nodal metastasis present | ||
| - No | 389 (50.4%) | 293 (45.1%) |
| - Yes | 383 (49.6%) | 357 (54.9%) |
| Race | ||
| - Asian | 3 (0.4%) | 46 (7.1%) |
| - Black | 0 (0.0%) | 85 (13.1%) |
| - missing | 404 (52.3%) | 58 (8.9%) |
| - Other | 7 (0.9%) | 1 (0.2%) |
| - White | 358 (46.4%) | 460 (70.8%) |
| Age at diagnosis (± SD) | 59.9 ± 13.4 | 56.9 ± 12.8 |
| Receptor subtype | ||
| - missing | 0 (0.0%) | 52 (8.0%) |
| - HER2 | 62 (8.0%) | 30 (4.6%) |
| - Luminal | 567 (73.4%) | 488 (75.1%) |
| - TNBC | 143 (18.5%) | 80 (12.3%) |
| ER status | ||
| - missing | 0 (0.0%) | 33 (5.1%) |
| - negative | 212 (27.5%) | 172 (26.5%) |
| - positive | 560 (72.5%) | 445 (68.5%) |
| PR status | ||
| - missing | 0 (0.0%) | 36 (5.5%) |
| - negative | 384 (49.7%) | 231 (35.5%) |
| - positive | 388 (50.3%) | 383 (58.9%) |
| HER2 status | ||
| - missing | 0 (0.0%) | 210 (32.3%) |
| - negative | 652 (84.5%) | 334 (51.4%) |
| - positive | 120 (15.5%) | 106 (16.3%) |
| Menopause status | ||
| - missing | 1 (0.1%) | 57 (8.8%) |
| - post | 584 (75.6%) | 441 (67.8%) |
| - pre | 187 (24.2%) | 152 (23.4%) |
| Tumor size* | ||
| - T1 (<20 mm) | 356 (46.1%) | 187 (28.9%) |
| - T2 (>20 <50 mm) | 391 (50.6%) | 389 (59.9%) |
| - T3&4 (>50 mm) | 25 (3.2%) | 73 (11.2%) |
| AJCC Stage | ||
| - I | 254 (32.9%) | 123 (18.9%) |
| - II | 443 (57.4%) | 376 (57.8%) |
| - III&IV | 75 (9.7%) | 132 (20.3%) |
| - missing | 0 (0.0%) | 19 (2.9%) |
Abbreviations: HER2, human epidermal growth factor receptor 2; TNBC, triple negative/basal breast subtype; ER, estrogen receptor; PR, progesterone receptor.
*Tumor size is AJCC TNM staging.